Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Public ClinicalTrials.gov record NCT07104565. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Study identification
- NCT ID
- NCT07104565
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Interventions
- INCA000585 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 28, 2025
- Primary completion
- Sep 22, 2027
- Completion
- Mar 8, 2028
- Last update posted
- May 7, 2026
2025 – 2028
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palo Verde Cancer Specialists Palo Verde Hematology Oncology, Ltd Glendale | Glendale | Arizona | 85304 | Recruiting |
| Usc Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| Rocky Mountain Cancer Centers | Lone Tree | Colorado | 80124 | Not yet recruiting |
| Yale University School of Medicine | New Haven | Connecticut | 06510 | Not yet recruiting |
| Gnp Research | Cooper City | Florida | 33024 | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Recruiting |
| Montefiore Medical Center | The Bronx | New York | 10461 | Recruiting |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031-4867 | Not yet recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Not yet recruiting |
| Versiti Bloodcenter of Wisconsin Bcw Milwaukee | Milwaukee | Wisconsin | 53233 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07104565, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07104565 live on ClinicalTrials.gov.